Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines

• Main Authors: Nai-Xiong Peng, Chun-Xiao Liu, Xi-Sheng Wang, Ze-Jian Zhang, Su-Cai Liao
• Format: Article
• Language: English
• Published: Bangladesh Pharmacological Society 2015-12-01
• Series: Bangladesh Journal of Pharmacology
• Subjects: Anti-cancer; Axitinib; Dasatinib; Prostate cancer cell line
• Online Access: https://www.banglajol.info/index.php/BJP/article/view/24149

Prostate cancer is the major cause of cancer-related deaths worldwide in men. There are new treatment methods and drugs are being developed with promising results in two of the prostate cancer cell lines (PPC-1 and TSU-Pr1). These two cells were treated with 20 uM of axitinib combined with dasatinib for 6-72 hours. The cell viability assessed by the cytotoxicity assay. Various regulatory genes such as c-KIT, cell cycle and apoptosis and angiogenic factors were also studied. The enzyme activity of apoptosis effector caspase-3 was colorimetrically determined. Axitinib and dasatinib combination lowered the survival rate of PPC-1 cells but enhanced the survival rate of TSU-Pr1 cells. The protein expression levels in apoptosis and angiogenesis factors were also found to be in contrast between the two cell lines. PPC-1 and TSU-Pr1 cells displayed a different response to axitinib with dasatinib, which explains different expression levels of regulators of cell-cycle, apoptosis and angiogenesis.